Physician profile
Mayank C Patel
NPI 1104914407
$3,942.08
in general payments reported to CMS, 2019-2025
24 companies · $814 in 2025
The $814 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $260 · 2021: $214 · 2022: $350 · 2023: $705 · 2024: $732 · 2025: $814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,238 · Education: $13.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,238.41 |
| Education | $13.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,397.24 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Insmed, INC. | $500.81 | 2023-2025 | Arikayce, Brinsupri |
| Astrazeneca Pharmaceuticals LP | $377.57 | 2019-2025 | Airsupra, Breztri, Fasenra |
| Mylan Specialty L.P. | $252.91 | 2019-2024 | Yupelri |
| Philips North America LLC | $193.61 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $182.22 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.76 | 2019-2023 | Ofev |
| Abiomed | $140.47 | 2025 | |
| Genzyme Corporation | $130.56 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $128.00 | 2023-2025 | Dupixent |
| Heartflow, INC. | $109.86 | 2023 | Ffrct |
| Actelion Pharmaceuticals US, INC. | $81.84 | 2019-2022 | |
| Inspire Medical Systems, INC. | $36.17 | 2024-2025 | Inspire |
| Shionogi INC | $33.48 | 2024 | Fetroja |
| Pulmonx Corporation | $26.27 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $25.41 | 2024 | |
| Jazz Pharmaceuticals INC. | $22.05 | 2024 | |
| Merck Sharp & Dohme LLC | $21.78 | 2023 | |
| Optinose US, INC. | $20.11 | 2022 | |
| Resmed Corp | $17.85 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $17.49 | 2021 | |
| Janssen Pharmaceuticals, INC | $17.34 | 2019 | |
| Phadia US INC. | $15.99 | 2024 | Immunocap |
| Electromed, INC. | $15.29 | 2023 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mayank Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.